1190002N15Rik Activators encompass a suite of chemical compounds that, through various mechanisms, are capable of enhancing the functional activity of 1190002N15Rik without directly increasing its expression. Forskolin, by elevating cAMP, indirectly augments 1190002N15Rik's activity through PKA activation, which in turn can initiate a cascade of intracellular signaling events where 1190002N15Rik is a participant. Sildenafil Citrate and IBMX, through the inhibition of phosphodiesterases, prevent the breakdown of cAMP, bolstering the cAMP-mediated signaling pathways that impinge on 1190002N15Rik function. Similarly, Rolipram, by selectively inhibiting PDE4, and Anagrelide and Cilostazol, by blocking PDE3, maintain elevated cAMP levels, indirectly facilitating the enhancement of1190002N15Rik Activators. These activators influence a spectrum of signaling pathways, ultimately converging on the functional upregulation of 1190002N15Rik. Compounds like Forskolin, Sildenafil Citrate, IBMX, and Rolipram operate through the elevation of intracellular cyclic AMP (cAMP) levels. Forskolin directly stimulates adenylyl cyclase, while Sildenafil Citrate and IBMX inhibit phosphodiesterase (PDE) enzymes, preventing cAMP degradation. Rolipram specifically inhibits PDE4, leading to a similar outcome.
Dopamine, with its pleiotropic effects, can also increase cAMP in certain cellular contexts by interacting with its G-protein-coupled receptors, which might lead to the enhancement of 1190002N15Rik activity. Anagrelide and Cilostazol, as PDE3 inhibitors, increase cAMP levels, offering a potential for amplifying PKA-mediated signaling impacting 1190002N15Rik. These chemical activators, through their direct and indirect actions, enhance the functional activity of 1190002N15Rik. They do so by influencing pathways that do not merely alter the quantity of 1190002N15Rik but modify the cellular context in which it operates, thus facilitating an increase in its functional activity without directly targeting the protein or its immediate receptors.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX, a non-selective inhibitor of phosphodiesterases, increases levels of cAMP and cGMP, which may enhance 1190002N15Rik activity by promoting signaling pathways that rely on these cyclic nucleotides. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, another selective PDE4 inhibitor, elevates intracellular cAMP, potentially enhancing the activity of 1190002N15Rik by activating PKA and affecting downstream targets. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine activates adrenergic receptors leading to increased cAMP and activation of PKA, which could enhance the activity of 1190002N15Rik through downstream effects on signaling pathways. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
PGE1 activates its GPCR, leading to an increase in cAMP. Elevated cAMP may enhance 1190002N15Rik activity by stimulating PKA and affecting the signaling cascades. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a synthetic catecholamine and β-adrenergic agonist, increases cAMP levels, potentially enhancing 1190002N15Rik activity through PKA activation. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits PDE3, increasing cAMP levels. This upsurge in cAMP may indirectly enhance 1190002N15Rik activity by modulating PKA-dependent signaling pathways. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol, a PDE3 inhibitor, augments cAMP levels, which could enhance the activity of 1190002N15Rik by affecting PKA and subsequent signaling pathways. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine can increase cAMP in certain contexts by activating dopamine receptors, potentially enhancing 1190002N15Rik activity through cAMP-dependent signaling pathways. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
Terbutaline, a β2-adrenergic receptor agonist, can increase cAMP levels, possibly enhancing the activity of 1190002N15Rik via the activation of PKA and downstream signaling. | ||||||